
Dir. of IBD @gastrorockies | Clinical Instructor @CUMedicalSchool | @UChicagoIBD @Georgetown GI trained | @ABC @AmCollegeGastro #YPLSP alum |tweets ≠ med advice
- Tweets3.3K
- Following851
- Followers2.9K
- Likes16.6K

ALT This image contains an excerpt from the Research Summary "Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis” published in the New England Journal of Medicine. It details participant demographics: 252 adults; mean age, 42 years (men: 58%; women: 42%). To the right, there is an illustration of a patient with ulcerative colitis. Below are boxes and tablets for the three tested icotrokinra doses (400 mg, 200 mg, and 100 mg) and placebo. A prompt to read the full Research Summary at NEJM.org sits at the bottom.

ALT A figure from an Original Article published in the New England Journal of Medicine article titled "Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis.” The figure shows the clinical response at week 12. The trial name, ANTHEM-UC, is in parentheses after the title. The NEJM identity sits at the bottom.



















































